RT Journal Article
SR Electronic
T1 Exploring the Potential of Large Language Models in Personalized Diabetes Treatment Strategies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.30.23292034
DO 10.1101/2023.06.30.23292034
A1 Yang, Hao
A1 Li, Jiaxi
A1 Liu, Siru
A1 Du, Lei
A1 Liu, Xiali
A1 Huang, Yong
A1 Shi, Qingke
A1 Liu, Jialin
YR 2023
UL http://medrxiv.org/content/early/2023/07/01/2023.06.30.23292034.abstract
AB This study aims to explore the application of a fine-tuned model-based outpatient treatment support system for the treatment of patients with diabetes, and evaluate its effectiveness and potential value.Methods The ChatGLM model was selected as the subject of investigation and trained using the P-tuning and LoRA fine-tuning methods. Subsequently, the fine-tuned model was successfully integrated into the Hospital Information System (HIS). The system generates personalized treatment recommendations, laboratory test suggestions, and medication prompts based on patients’ basic information, chief complaints, medical history, and diagnosis data.Results Experimental testing revealed that the fine-tuned ChatGLM model is capable of generating accurate treatment recommendations based on patient information, while providing appropriate laboratory test suggestions and medication prompts. However, for patients with complex medical records, the model’s outputs may carry certain risks and cannot fully substitute outpatient physicians’ clinical judgment and decision-making abilities. The model’s input data is confined to electronic health record (EHR), limiting the ability to comprehensively reconstruct the patient’s treatment process and occasionally leading to misjudgments of the patient’s treatment goals.Conclusion This study demonstrates the potential of the fine-tuned ChatGLM model in assisting the treatment of patients with diabetes, providing reference recommendations to healthcare professionals to enhance work efficiency and quality. However, further improvements and optimizations are still required, particularly regarding medication therapy and the model’s adaptability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Key Research and Development Program: Construction of a Big Data Cloud Service Platform for Health Examinations(2020YFC2003404)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Ethics Committee of West China Hospital, Sichuan University (2021-1450).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors